Shares of Dr Reddy's Laboratories Ltd witnessed heavy volatility Friday, recovering most of its sharp early losses to end over 4 per cent down.
The company's stock tumbled 22.62 per cent to Rs 2,065.30 intra-day on the BSE. Later, it recovered most of the losses and closed 4.21 per cent lower at Rs 2,556.90.
At the National Stock Exchange (NSE), shares crashed 29.77 per cent to Rs 1,872.95 apiece -- its 52-week low in intra-day. It later closed at Rs 2,563.35, a fall of 3.89 per cent.
On the traded volume front, 4.94 lakh shares traded on the BSE and over 67 lakh shares on the NSE.
The stock reeled under selling pressure amid reports that research firm Jefferies said 11 FDA observations under Form 483 on a unit of the drug firm included four repeat observations.
On February 8, Dr Reddy's in a filing to the BSE said, "This is to inform you that the audit of our formulations manufacturing plant - 3 at Bachupally, Hyderabad by the US FDA, has been completed. We have been issued a Form 483 with 11 observations."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
